Genes that may help predict response to BRAF inhibitors for advanced melanoma identified

Genetic analysis of the tumors from patients with advanced melanoma can clue researchers in to how well patients will respond to therapies targeting the growth-promoting protein called BRAF, researchers report. Looking outside of the BRAF gene, the researchers found loss of the tumor suppressor gene PTEN also appears to be associated with patient response to GSK436.

Read the whole article on Science Daily

More from Science Daily